Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
RESEARCH TOOLSreports
Holding AMPH?
Track your performance easily
AMPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$36.56 - $65.92
Previous Close$45.46
Volume410.77K
Average Volume (3M)350.16K
Market Cap
$2.19B
Enterprise Value$2.57B
Total Cash (Recent Filing)$250.49M
Total Debt (Recent Filing)$629.85M
Price to Earnings (P/E)15.1
Beta0.77
Next Earnings
Mar 12, 2025EPS Estimate
$0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.00
Shares Outstanding48,081,433
10 Day Avg. Volume531,255
30 Day Avg. Volume350,157
Standard Deviation0.11
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.91
Price to Sales (P/S)2.90
Price to Cash Flow (P/CF)8.70
P/FCF Ratio11.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit7.31
Enterprise Value/Ebitda9.63
Forecast
1Y Price Target
$63.67Price Target Upside40.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Amphastar Pharmaceuticals News
PremiumCompany Announcements
Amphastar Pharmaceuticals Reports Strong Q3 2024 Results
PremiumCompany Announcements
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
Bulls Say, Bears Say
Bulls Say
Financial Health And Business DevelopmentAmphastar Pharmaceuticals is well-positioned for business development with over $200 million in cash and a net leverage ratio below 2x, highlighting strong financial health.
Market Leadership And Sales StrategyBAQSIMI leads the branded glucagon market as the only non-injectable product, with plans to expand its sales force to drive anticipated growth.
Product Pipeline And ApprovalsAMPH could see 2-3 new product approvals, with several more launches filed for regulatory review, indicating a robust pipeline.
Bears Say
Financial PerformanceThird-quarter results fell short of market expectations, missing estimates for both revenue and profit.
Product Approval DelaysThe AMP-002 product remains unresolved with no clear timeline for approval, alongside delays in other expected product approvals.
Regulatory ChallengesRegulatory actions have delayed potential product launches, contributing to weak stock performance compared to industry benchmarks.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AMPH FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was $36.56 and its highest was $65.92 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Currently, no data Available
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Mar 12, 2025 which is in 108 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $0.96 earnings per share for the quarter, missing the consensus estimate of $0.988 by -$0.028.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is $0.96.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 48,081,432 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of $0.96 in its last earnings report, missing expectations of $0.988. Following the earnings report the stock price went down -13.689%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Among the largest hedge funds holding Amphastar Pharmaceuticals’s share is Hotchkis & Wiley Capital Management LLC. It holds Amphastar Pharmaceuticals’s shares valued at 11M.
---
Amphastar Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.67 (40.06% Upside)
$63.67 (40.06% Upside)
Blogger Sentiment
Bullish
AMPH Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 166.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.89%
12-Months-Change
Fundamentals
Return on Equity
23.85%
Trailing 12-Months
Asset Growth
0.04%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
AMPH Company Deck
---
AMPH Earnings Call
Q3 2024
0:00 / 0:00
---
AMPH Stock 12 Month Forecast
Average Price Target
$63.67
▲(40.06% Upside)
Technical Analysis
Best Analysts Covering AMPH
1 Year
1 Year Success Rate
15/18 ratings generated profit
1 Year Average Return
+23.56%
assigned a buy rating last month
Copying Tim Chiang's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +23.56% per trade.
---